Skip to content

Altimmune ALT Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)

Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) at other companies

Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$61.35M-6.8%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$66.81M-64.8%

Other financials

Income statement

See full
Revenue$26.0K+420%
Operating income-$24.2M-11.1%
Net income-$22.6M-15.3%
EPS (diluted)-$0.18+30.8%

Balance sheet

See full
Cash & equivalents$97.6M+98.7%
Total debt$34.8M+14,092%
Total equity$284.0M+99.8%
Total assets$335.6M+113%

Cash flow

See full
Operating cash flow-$20.9M-24.4%
CapEx$21.0K
Free cash flow-$21.0M

Valuation

See full
Market cap$558.14M-2.1%
Enterprise value$495.27M-5.0%
P/S13,613.2×-24,380×

Profitability

See full
Operating margin-230,461%-82,087pp
Net margin-214,861%-76,057pp
FCF margin-17,806.8%-110,030pp

Returns & leverage

See full
Return on equity-42.7%-8.7pp
Debt / equity0.1×+0.1×
Current ratio29.6×+13.7×

Where this comes from

Reported directly by Altimmune in its filing.

Tagged under the XBRL concept us-gaap:ShortTermInvestments.

The official record: Altimmune’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Altimmune's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Altimmune's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)?
Altimmune (ALT) reported short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) of $233.94M in Q1 2026.
How has Altimmune's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) changed year-over-year?
Altimmune's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) increased by 132.3% year-over-year, from $100.72M to $233.94M.
What is the long-term trend for Altimmune's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)?
Over 4 years (2020 to 2025), Altimmune's short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) has grown at a 23.1% compound annual growth rate (CAGR), from $100.01M to $229.7M.
What does short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84) mean?
This represents financial instruments held by the company with maturities greater than one year that are intended to be held for investment purposes rather than immediate liquidity. These assets are often managed to generate returns on excess cash while maintaining a degree of flexibility for future capital needs. It may include restricted assets associated with specific consolidated entities.